Taltirelin

IDrugs

Volumn 2, Issue 10, 1999, Pages 1059-1068

  Tanabe, Seiyaku ^a   Brown, William ^a  

^a Taro Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AZETIRELIN; DOPAMINE; GAMMA BUTYROLACTONE GAMMA CARBONYLHISTIDYLPROLINAMIDE CITRATE; MONTIRELIN; POSATIRELIN; PROTIRELIN; PROTIRELIN DERIVATIVE; PROTIRELIN RECEPTOR; PROTIRELIN[3 (3,3 DIMETHYLPROLINAMIDE)]; PYRO 2 AMINOADIPYLHISTIDYLTHIAZOLIDINE 4 CARBOXAMIDE; TALTIRELIN;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DEMENTIA; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG INDICATION; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; FLEXOR REFLEX; HUMAN; INTRADUODENAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MENTAL HEALTH; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SPINAL REFLEX; STRUCTURE ACTIVITY RELATION;

EID: 0032851423     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. 35018 Pharmacological study of TA-0910, a new thyrotropinreleasing hormone (TRH) analog, (I): Effects on the central nervous system by oral administration. Yamamura M, Kinoshita K, Nakagawa H, Tanaka T, Maeda K, Ishida R JPN J PHARMACOL 199053451-461
2. Taltirelin shortened pentobarbital-induced sleep and antagonized reserpine-induced hypothermia.
3. 35019 Synthesis and central nervous system actions of thyrotropin-releasing hormone analogues containing a dihydroorotic acid moiety. Suzuki M, Sugano H, Matsumoto K, Yamamura M, Ishida R J MED CHEM1990 33 8 2130-2137
4. Major study describing synthesis and screening for CNS effects of more than 30 TRH analogs. Taltirelin was the most potent compound with regard to CNS effects.
5. 35020 Attenuation of alcohol preference in alcohol-preferring rats by a novel TRH analogue, TA-0910. Rezvani AH, Garbutt JC, Shimoda K, Garges PL, Janowsky DS, Mason GA ALCOHOL CLIN EXP RES 1992 16 326-330
6. 35021 TA-0910. DRUGS FUTURE 1992 17 2 163-164
7. 35022 TA-0910. TRH analog, cognition enhancing agent. DRUGS FUTURE 1991 16 2 127-129
8. 35023 Pharmacological study of TA-0910, a new thyrotropinreleasing hormone (TRH) analog (IV): Effects on experimental memory impairment in mice and rats. Yamamura M, Kinoshita K, Nakagawa H, Ishida R JPN J PHARMACOL 1991 55 2 241-253
9. 35024 Pharmacological study of TA-0910, a new thyrotropinreleasing hormone (TRH) analog (III): Inhibition of pentobarbital anesthesia. Yamamura M, Kinoshita K, Nakagawa H, Ishida R JPN J PHARMACOL 1991 55 1 69-80
10. 35025 Pharmacological study of TA-0910, a new thyrotropinreleasing hormone (TRH) analog (II): Involvement of the DA system in the locomotor stimulating action of TA-0910. Yamamura M, Kinoshita K, Nakagawa H, Ishida R JPN J PHARMACOL 1991 55 1 57-68
11. 117462 TRH analogue, TA-0910 (3-methyl-(s)-5,6-dihydroorotylL-histidyl-L-prolinamide) enhances neurite outgrowth in rat embryo ventral spinal cord In vitro. Iwasaki Y, Ikeda K, Shiojima T, Kinoshita M JNEUROL SC11992 112 147-151
12. 148668 Ameliorating effect of TA-0910, a novel TRH analog, on ataxia models. Kinoshita K, Fujitsuka T, Yamamura M, Ishida R JPN J PHARMACOL 1992 59 Suppl 1 177P
13. 154099 NMEs and biologicals reported for the first time - List 10. Suzuki M, Sugano H, Matsumoto K, Yamamura M, Ishida R DRUG NEWS PERSPECT1990 3 10 616-617
14. 157450 TA-0910. DRUGS FUTURE 1994 19 2 202 163501 Tanabe Selyaku Co Ltd. ANNUAL REPORT 1994
15. 166356 A radioimmunoassay for TA-0910, a new metabolically stable thyrotrophin-releasing hormone analogue. Chishima S J PHARM BIOMEDANAL 1994 12 6 795-804
16. 166358 Alteration by prolonged oral administration of a thyrotropin-releasing hormone analog, TA-0910, of the pituitary-thyroid axis In subjects with brain stroke. Miyashita K, Murakami M, Satoh T, Monden T, Yamada M, Iriuchijima T, Kazihara A, Mon M INTERN MED 1993 32 9 681-685
17. Prolonged administration of taltirelin caused no change in the pituitary-thyroid axis in stroke patients.
18. 166359 Clinical dose-up trial of TA-0910 in the treatment of spinocerebellar degeneration. Yamada H, Yoshida M JPN PHARMACOL THE01993 21 6 231-240
19. Clinical dose-escalating study of taltirelin in patients with SCO.
20. 166360 TA-0910. DRUGS FUTURE 1993 18 2 190 174987 Tanabe Seiyaku Co Ltd. ANNUAL REPORT 1993
21. 175704 Anti-ataxic effects of thyrotropin-releasing hormone and its analog, TA-0910, in neurological mutant mice: Behavioral and autoradiographic study. Kinoshita K, Watanabe Y, Asai H, Yamamura M, Matsuoka Y JPN J PHARMACOL 1995 67 Suppl 1 223P
22. This review shows that the ataxia of RMN is due to dysfunction of the cerebullum and ventral tegmentum area (VTA), and that amelioration by TRH and taltirelin is due to the functional normalization of the VTA.
23. 175706 Effects of TA-0910 (TRH analog) and TRH on electrocardiograms in dogs. Kato M, Yamada S, Yamaguchi K, Kyuki K, Yamamura M JPN J PHARMACOL 1995 67 Suppl 1 223P
24. Taltirelin is more potent than TRH and its effect is long-lasting. The arousal effect of taltirelin is mediated by activating the cholinergic system.
25. 176564 TA-0910. DRUGS FUTURE 1995 20 2 217
26. 181449 Effects of TA-0910, an orally active TRH analog, on the spinal reflex In spinal rats. Kinoshita K, Nagao T, Ono H NEUROPHARMACOLOGY1994 33 10 1183-1188
27. 187664 New drugs in the R&D pipeline. PHARMA JPN1995 1466 19
28. 192744 Effects of TA-0910, a novel orally active thyrotropinreleasing hormone analog, on the gait of ataxic animals. Kinoshita K, Fujitsuka T, Yamamura M, Matsuoka Y EUR J PHARMACOL 1995 274 1-3 65-72
29. 192745 Effects of TA-0910, an orally active TRH analog, on the spinal reflex in spinal rats. [Erratum to document cited in CA121:2725971]. Kinoshita K, Nagao T, Ono H NEUROPHARMACOLOGY199433 12 1613
30. 211772 New drugs in the R&D pipeline...Tanabe. PHARMA JPN 1996149420
31. 213434 Information update. Lazarewicz JW, Salinska E, Spenia E, Gadamski R DRUGS FU71V7E1996 21 2 191-232
32. 214248 Effects of TA-0910 (TRH analog) and TRH on electrocardiograms in dogs. Kato M, Yamada S, Yamaguchi K, Kyuki K, Yamamura M JPN J PHARMACOL 1995 67 Suppl 1 Ab P2-231
33. 234108 Effect of TA-0910, a novel thyrotropin-releasing hormone analog, on in vivo acetylcholine release and turnover in rat brain. Kinoshita K, Kawashima K, Kawashima Y, Fukuchi I, Yamamura M, Matsuoka Y JPN J PHARMACOL 1996 71 2 139-145
34. 237434 Thyrotropin-releasing hormone analog TA-0910 reduces voluntary alcohol intake of P rats subchronically in a limited scheduled access paradigm. Mason GA, Rezvani AH, Overstreet DH, Garbutt JC ALCOHOLISM 1996 20 6 1000-1003
35. 241500 Distribution of thyrotropin-releasing hormone (TRH) receptors in the brain of the ataxic mutant mouse, rolling mouse Nagoya. Kinoshita K, Yamamura M, Sugihara J BIOL PHARMBULL 199720 1 86-87
36. 241501 Chronic anti-ataxic actions of the novel thyrotropinreleasing hormone (TRH) analog, TA-0910, during and after repeated administration in rolling mouse Nagoya: Behavioral and pharmacokinetic studies. Kinoshita K, Fukushima T, Kodama Y, Sugihara J, Yamamura M, Matsuoka Y BIOL PHARMBULL 1997 20 1 36-39
37. Anti-ataxic effects were seen up to 3 weeks after the last dose of taltirelin,
38. 241502 Electrophysiological evaluation of the demented state and the nootropic effect of TA-0910 by "automated fluctuation analysis" of the high-frequency EEC - relation between neuropsychological test results and Lorentzian parameters.
39. Electrophysiological evaluation of demented patients taking taltirelin.
40. 241503 Effect of (-)-N-[(S)-hexahydro-l-methyl-2,6-dioxo-4-pyrimidinylcarbonyl]-L-histidyl-L- prolinamide (TA-0910), a new TRH analog, on plasma levels of TSH and thyroid hormones in rats. Moriyasu M, Nasu M, Honda H, Sakamoto T, Yamamura M, Matsuoka Y FOLIA PHARMACOL JPN 1996107 6 285-297
41. 241505 TA-0910. DRUGS FUTURE 1996 21 2 229-230
42. 246765 Altered ligand dissociation rates in thyrotropinreleasing hormone receptors mutated in glutamine 105 of transmembrane helix III. del Camino D, Barras F, Pardo LA, de Lapena P BIOCHEMISTRY 1997 36 11 3308-3318
43. 246766 Local hormone networks and intestinal T' cell homeostasis. Wang J, Whetsell M. Klein JR SCIENCE 1997 275 5308 1937-1939
44. 248808 Thyrotropin releasing hormone analog TA-0910 suppresses alcohol intake In alcohol drinking African green monkeys. Rezvani AH, Garbutt JC, Overstreet DH, Li L, Walker CH, Yang Y, Mason GA ALCOHOL CLIN EXP RES 1997 21 2 261-266
45. 248809 A novel thyrotropin-releasing hormone analog, TA0910, ameliorates 3-acetylpyridine-induced ataxia through NMDA receptors in rats. Kinoshita K, Watanabe Y, Yamamura M, Malsuoka Y JPN J PHARMACOL 1997 73 Suppl 1 59P
46. 248811 Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area. Kinoshita K, Watanabe Y, Asai H, Yamamura M, Matsuoka Y BR J PHARMACOL 1995 116 8 3274-3278
47. 248812 Involvement of 02 receptors in the suppressive effect of the TRH analog TA-0910 on alcohol intake. Rezvani AH, Garbutt JC, Mason GA SOC NEUROSCIABSTR1995 21 1-3 1703
48. 248813 Microinjection of TRH analogue into the dorsal vagal complex stimulates pancreatic secretion in rats. Okumura T, Taylor IL, Pappas TN AMJPHYSIOL 1995 269 3 Pt 1 G328-G334
49. 248814 The subchronic effects of the TRH analog TA-0910 and bromocriptine on alcohol preference in alcohol-preferring rats: development of tolerance and cross-tolerance. Mason GA, Rezvani AH, Grady DR, Garbutt JC ALCOHOLISM 1994 18 5 1196-1201
50. 248816 A refined evaluation of cerebellar ataxia and its application to treatment of spinocerebellar degeneration. Takayanagi T CLIN NEUROL 1993 33 12 1297-1299
51. 248818 Neurochemical study of TA-0910 a new TRH analog. 5 Effects of chronic treatment on TRH muscarinic acetylcholine muscarinic and D, dopamine receptors in rat brain. Fukuchi I, Asahi T, Yamamura M, Matsuoka Y, Ishida R JPN J PHARMACOL 199361 SuppM 249P
52. 248819 Attenuation of alcohol preference in alcohol-preferring rats by a novel TRH analogue, TA-0910. Rezvani AH, Garbutt JC, Shimoda K, Garges PL, Janowsky DS, Mason GA ALCOHOLISM 1992162326-330
53. 248821 Neurochemical study of TA-0910 a new TRH analog 3. Effect on acetylcholine metabolism In rat brain. Shibutani Y, Kawashima K, Fujuhi I, Yamamura M, Matsuoka Y, Ishida R JPN J PHARMACOL 1992 59 Suppl 1 95P
54. 248822 Neurochemical study of TA-0910 a new TRH analog. Effect on acetylcholine release in rat hippocampus. Kawashima K, Shibutani Y, Fukuchi I, Yamamura M, Matsuoka Y, Ishida R JPN J PHARMACOL 1992 59 Suppl 1 88P
55. 248823 The potentiating effect of TA-0910 a new TRH analog on the central muscarinic cholinergic system in probably in part due to its inhibition of desensitization of muscarinic acetylcholine receptors. Kudo Y, Sumikawa H, Ishida R JPN J PHARMACOL 1990 52 Suppl 1 99P
56. 248826 Neurochemical study of TA-0910, a new TRH analog 1. Effect of monoamines metabolism in rat brain. Fukuchi I, Kawahima K, Shibutani Y, Yamamura M, Ishida R JPN J PHARMACOL 1991 55 Suppl 1 113P
57. 248828 Neurochemical study of TA-0910, a new TRH analog 2. Effect on dopamine release In rat brain. Kawashima K, Fukuchi I, Shibutani Y, Yamamura M, Ishida R JPN J PHARMACOL 1991 55 Suppl 1 113P
58. 254556 TA-0910, Taltirelin. DRUGS FUTURE 1997 22 2 207-208
59. 261882 TRH and Alzheimer's disease. Peabody ÇA, Deblois TE, Tinklenberg JR AM J PSYCHIATRY 1986 143 262-263
60. According to the authors, the first reported use of TRH to treat AD.
61. 262184 Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Mellow AM, Sundertand T, Cohen RM, Lawlor BA, Hill JL, Newhouse PA, Cohen MR, Murphy DL PSYCHOPHARMACOLOGY1989 98403-407
62. 262186 Biologically stable analogues of TRH with increased neuropharmacological potency. Brewster D, Dettmar PW, Metcalf G NEUROPHARMACOLOGY1981 20497-503
63. 262189 Presser, norepinephrine, and pituitary responses to two TRH doses in Alzheimer's disease and normal older men. Lampe TH, Veith RC, Plymate SR, Risse SC, Kopeikin H, Cubberty L, Raskind MA PSYCHONEUROENDOCRINOL198914 311-320
64. 262192 TSH responses to two TRH doses in men with Alzheimer's disease. Lampe TH, Plymate SR, Risse SC, Kopeikin H, Cubberty L, Raskind MA PSYCHONEUROENDOCRINOL 1988 13 245-254
65. 262193 The therapeutic potential of thyrotropin releasing hormone in Alzheimer's disease. Yarbrough GG, Pomara N PROG NEURO PSYCHOPHARMACOL BIOL PSYCHIATRY1985 9 285-289
66. 262202 Effects of peptide structure on transport properties of seven thyrotropin releasing hormone analogues in a human intestinal cell line (Caco-2). Wemer U, Kissel T, Stuber W PHARM RES 1997 14 246-250
67. 262238 A refined model of the thyrotropin releasing hormone receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Pertman JH, Laakkonen U, Guamieri F, Osman R, Moeller KD, Gershengorn MC BIOCHEMISTRY'1996 35 7643-7650
68. 262252 Cloning and expression of the thyrotropin releasing hormone receptor from GH3 rat anterior pituitary cells, de la Pena P, Delgano LM, del Camino D, Barras F BIOCHEM J 1992 284 Pt 3 891-899
69. 262259 Clinical phase I study of TA-0910. Oral repeated dose study. Kainuma H, Morikawa S, Tagawa K, Murata K, Banno K, Sato T, Takai T, Suzuki T RINSHO IYAKU 1997 13 2517-2532
70. 262261 Clinical phase I study of TA-0910. Oral single dose study Kainuma H, Morikawa S, Tagawa K, Murata K, Banno K, Sato T, Takai T, Suzuki T RINSHO IYAKUW97 13 2501-2516
71. 262279 A study of heel-knee tapping test in cerebellar ataxia by a motion measurement system. Ando N, Fujimoto Y, Takayanagi T, Ando M, Mano Y RINSHO SHINKEIGAKU1995 35 733-737
72. 262280 Effect of TA-0910 on the levels of monoamine metabolites in rat brains. Araki Y, Wakata N, Sumiyoshi S, Niizuma M, Kinoshita M SH1NKEI CHIRYOGAKU1995 12 45-48
73. 262282 The effects of TA-0910 on spinocerebellar degeneration as determined by a new gait analysis. Ando N, Fujimoto Y, Takayanagi T, Mano Y SHINKEI CHIRYOGAKU1993 10 217-221
74. 262283 Clinical evaluation of TA-0910 in the treatment of spinocerebellar degeneration. Yanagimoto S, Takayanagi T, Tamura R, Fujimoto Y, Murata K, Matsumura R, Sugata T, Ikoma K, Mano Y SHINKEI NAIKA CHIRYO 1991 8 311-316
75. 262647 Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E J NEUROSC11997 17 16 6401-6408
76. 263997 Discovery of Taltirelin hydrate (TA-0910), an orally active TRH analog with long-lasting CNS actions. Kinoshita K, Yamamura M, Suzuki M, Matsumoto K AFMC INT.MED CHEM SVMP1997 Jul-Aug90
77. 273705 Synthesis and pharmacological action of TRH analog peptide (Taltirelin). Yamamura M, Suzuki M, Matsumoto K FOLIA PHARMACOL JPNW97 110 Suppl 1 33P-38P
78. 276234 TRH-analog, TA-0910 (3-methyl-(s)-5,6-dihydroorotylL-histidyi-L- prolinamide) rescues motor neurons from axotomy-induced cell death. Iwasaki Y, Shiojima T, Tagaya N, Kobayashi T, Kinoshita M NEUROL RES 1997 19 6 613-616
79. 276248 Oncogenicity studies of taltirelin tetrahydrate (TA0910) by oral gavage administration in CD-1 mice and CD rats. Yamamura T, Nishimura T, Kuwamura Y, Inui T, Aughton P, Kawai Y J TOXICOL SC11997 22 Suppl 2 419-430
80. 276323 Repeated dose toxicity studies of taltirelin tetrahydrate (TA-0910) with oral administration to dogs. Inui T, Yuasa H, Adachi T, Kawai Y, Kudow S J TOXICOL SC11997 22 Suppl. 2 357-369
81. 276324 Acute toxicity studies of taltirelin tetrahydrate in mice, rats, and dogs. Hishida N, Kuse H, Yamamura T, Noguchi M, Kawai Y, Hori M J TOXICOL SC11997 22 Suppl 2 327-334
82. 279572 Searle/Pfizer to co-promote Célébra: NDA filing expected by year-end. FDC REPORTS PINK SHEET 1998 60 8
83. 280463 Involvement of dopamine D, receptors in the suppressive effect of the thyrotropin-releasing hormone analog TA-0910 on alcohol intake in alcohol-preferring rats. Mason GA, Rezvani AH, Overstreet DH, Hamedi M, Walker CH, Yang Y, Garbutt JC ALCOHOLISM 1997 21 9 1623-1629
84. 280581 Repeated dose toxicity studies of taltirelin tetrahydrate (TA-0910) by oral administration to rats. Inui T, Fujiwara T, Susami M, Hishida N, Kuwamura Y, Kuse H, Kawai Y, Kudow S J TOXICOL SC11997 22 Suppl 2 335-356
85. 281057 Pharmaceutical Industry: Global Model Book Highlights: Models for the US, Europe, Emerging Europe and Japan. Merrill Lynch ANALYST REPORT 1998
86. 283362 General pharmacology of taltirelin hydrate (TA-0910) 2. Effects on respiratory and cardiovascular systems, autonomie nervous system and smooth muscle, digestive system, renal function and somatic nervous system. Inamasu M, Kikkawa H, Nishiyama S, Yamaguchi K, Kato M, Kinoshita K, Yamamura M, Matsuoka Y PHARMACOMETRICS1997 54 6 361-381
87. 283364 Relation of pituitary-thyroid system to central stimulatory action of taltirelin hydrate (TA-0910), a new analog of thyrotropin-releasing hormone. Asahi T, Yamamura M PHARMACOMETRICS 1997 54 6 341-348
88. 289191 Radioimmunoassay for TA-0910, a new stable thyrotropin releasing hormone analogue and its metabolite, TA0910 acid-type, in human plasma and urine. Morikawa S, Sakai T, Murata K, Banno K, Sato T, Takai T, Suzuki T J PHARM BIOMEDANAL 1998 16 8 1267-1274
89. 289250 Effects of taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain. Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y, Kinoshita K ARZNEIMITTELFORSCHUNG 1998 48 4 353-359
90. 289284 TRH receptor agonists ameliorate 3-acetylpyridineinduced ataxia through NMDA receptors in rats. Kinoshita K, Watanabe Y, Yamamura M, Matsuoka Y EUR J PHARMACOL 1998 3432-3129-133
91. 296442 New drugs In the R&D pipeline. PHARMA JPN 1998 (Extra issue) 1611 24 August 1
92. 310638 Behavioral, pharmacological, and neurochemical assessment of psychological dependence potential of TA-0910. Toshio A, Hiroshi I, Michio Y JPN J PHARMACOL 1996 16 6 358
93. 310641 An update on the CNS actions of TRH and its analogs. Horita A LIFE SC11998 62 17-18 1443-1448
94. 310644 Phase I study of TA-0910. Influence Of food intake on pharmacoklnetics. Masami F, Hiao T, Nobuo T, Kenji T, Shigeki M, Kozo T, Masami M, Kazuo M, Tadashi S J CLIN THER MED 1997 13133359-3369
95. 310661 Reproductive and developmental toxicity studies of taltirelin hydrate (4): perinatal and postnatal study in rats by oral administration. Imahie H, Koguchi A, Kobayashi T, Asano Y J TOXICOL SC11997 22 Suppl 2 405-417
96. 310666 Reproductive and developmental toxicity studies of taltirelin hydrate (3): perinatal and postnatal study in rabbits by oral administration. Imahie H, Nishida A, Imado N, Asano Y J TOXICOL SC11997 22 Suppl 2 395-403
97. 310673 Reproductive and developmental toxicity studies of taltirelin hydrate (2): teratogenicity study in rats by oral administration. Imahie H, Kobayashi T, Nishida A, Imado N, Asano Y J TOXICOL SC11997 22 Suppl 2 381 -394
98. 310675 Reproductive and developmental toxicity studies of taltirelin hydrate (1): fertility study in rats by oral administration. Imahie H, Kobayashi T, Imado N, Inui T, Ariyuki F, Asano Y J TOXICOL SC11997 22 Suppl 2 371-379
99. 310677 Efficacy of the TRH derivative and TA-0910 on spinocerebellar degeneration. Teruhiko K, Yuichi T, Takako Y SHINRYO SHIN'YAKU 1997 34 7 701 -710
100. 310680 Endocrinologie evaluation of oral TRH derivative (TA0910) for spino-cerebellar degeneration. Tadanori Y, Motomori I, Shigenobu N, Mitsuhiro T CLIN ENDOCRINOL 1997 45 8 805-810
101. 310682 Examination of the effectiveness and safety of TA-0910 for an ataxia state of olivopontocerebellar atrophy. Examination using quantitative evaluation. Tokio S SHINRYO SHIN'YAKU 1997345539-546
102. 310686 Clinical study of TA-0910 in spinocerebellar degeneration. The effects of neurotransmitters In cerebrospinal fluid. Yoshiki A, Hiroshi T, Glen I, Yasuhiro W, Kenji N, Kazuo T KISO TO RINSHO (CLIN REP) 1997 31 7 2623-2630
103. 310689 Clinical evaluation of orally administered TRH derivative (TA-0910) for spinocerebellar degeneration. Makiko S, Satoshi S, Izumi O, Kunihiko C, Shigenobu N, Mitsuhiro T SHINRYO SHIN'YAKU 1994 31 2 275-281
104. 310690 Taltirelin hydrate (TA-0910): an orally active thyrotroplnreleasing hormone mimetic agent with multiple actions. Kinoshita K, Yamamura M, Sugihara J, Suzuki M, Matsuoka Y CNS DRUG REV 1998 4 125-41
105. 310711 Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration. A multi-center, double-blind, comparative study with placebo. Ichiro K, Eijiro S, Keizo H, Tetsuya T, Kazuro T, Hisayuki K, Kunio T, Mitsuhiro O, Mitsuyoshi N RINSHO IYAKU1997 13 16 4169-4224
106. A long-term, placebo-controlled, double-blind clinical trial demonstrating the efficacy (as measured by arrest of disease course and amelioration of ataxia) and safety of taltirelin in the treatment of SCO. Statistically significant improvements in the global improvement rating were observed in patients receiving the drug compared to those taking placebo.
107. 310712 The clinical evaluation of TA-0910 in spinocerebellar degeneration (SCO). A double blind cross-over comparative study vs placebo. Keizo H, Kimihito A, Kunio T, Tetsuya T, Kazuro T, Nobuya O RINSHO IYAKU 1997 13 16 4133-4167
108. 310713 Alternatives to naltrexone in animal models. Overstreet DH, McArthur R ALCOHOL CLIN EXP RES 1996 20 Suppl 8 231A-235A
109. 310714 Pharmacotherapies for alcohol problems: a review of research with a focus on developments since 1991. Litten RZ, Allen J, Fertig J ALCOHOL CLIN EXP RES 1996 20 5 859-876
110. 310715 Taltirelin TA-0910. DRUGS FUTURE 1998 23 2 245
111. 310716 Trophic effect of TA-0910 on the cultured ventral spinal ; cord of rat embryo. Ken I, Yasuo I, Toshiya S, Masao K SHINKEI CHIRYOGAKU1992 9 4 385-388
112. 310717 Role of the extracellular loops of the thyrotropinreleasing hormone receptor: evidence for an initial interaction with thyrotropin-releasing hormone. Perlman JH, Colson A-O, Jain R, Czyzewski B, Cohen LA, Osman R, Gershengom MC BIOCHEMISTRY 1997 36 50 15670-15676
113. 310718 Conformationally restricted TRH analogs: the compatibility of a 6,5-bicyclic lactam-foased mimetic with binding to TRH-R. Li W, Moeller KD J AM CHEM SOC1996118 42 10106-10112
114. 310719 Conformationally restricted TRH analogs: a probe for the pyroglutamate region. 'Rutiedge LD, Pertman JH, Gershengom MC, Marshall GR, Moeller KD J MED CHEM 1996 39 8 1571 -1574
115. 310739 Disposition of taltirelin. (1): absorption, distribution, metabolism and excretion in rats and dogs. Hirohiko K, Satoshi F, Masakatsu T, Juko S, Masayoshi Y XENOBIOT METAB DISPOS 1997125460-474
116. 310740 Disposition of taltirelin. (1): the transfers into the fetus and milk, sex-related difference after single oral dose administration and blood concentration after repeated oral dosing in rats. Hirohiko K, Akiko K, Juko S, Masayoshi Y XENOBIOT METAB DISPOS 1997 12 5 475-482
117. 310741 Disposition of taltirelin. (1): the transfer into the brain and brain distribution in rats. Hirohiko K, Takeshi F, Susumo C.-Juko S, Masayoshi Y XENOBIOT METAB DISPOS 199712 5 483-490
118. 319777 The Japanese Pharmacological Society 72nd Annual Meeting, Sapporo, Hokkaido, Japan. Wright T IDdb MEETING REPORT 1999 March 22-25
119. 322030 Effects of TRH analog, taltirelin hydrate (TA-0910), on the circulatory and respiratory failures and viable time following hemorrhagic shock in rats. Watanabe Y, Matsuoka Y, Kinoshita K JPN J PHARMACOL 1999 79 Suppl I 0-193
120. 323576 Diversity of thyrotropin-releasing hormone receptors in the pituitary and discrete brain regions of rats. Asai H, Kinoshita K, Yamamura M, Matsuoka Y JPN J PHARMACOL 1999 79 313-317
121. 323760 Brain local glucose metabolism (rCMGglc) facilitation by TA-0910 in Macaca mulatto. Examination with PET. Kohi T, Naoto H, Yoshihiro M NIPPON YAKUGAKKAINENKAIKOEN YOSHISHU1997 11735
122. 323761 Brain local glucose metabolism (rCMGglc) facilitation by TA-0910 in Macaca mulatto. Examination with PET. Hjoki T, Yoshihiro M, Naoto H NIPPON YAKUGAKKAI NENKAI KOEN VOSHISHÜ19971188
123. 323764 Efficacy of TRH analog (TA-0910) and L-threonine on spinocerebellar degeneration. Toshikazu T, Kazuko H, Eimei F, Tetsuo M, Hisayuki K ANN REP RES CMTEATAXIC DIS 1996 35
124. 323766 Clinical effects on cerebrovascular dementia of new cerebral function improvement medicine, TA 0910. Kazumi N, Masako F, Nobuyuki O et al RINSHO KENKYU1993 70 3347-3356
125. 323767 Evaluation of demented state by means of "automated fluctuation analysis". A study focused on the evaluation of the nootropic drug action of TA-0910. Munetomo N, Yoshiaki O, Kunimasa N IRYO JOHOGAKU RENGO TAIKAI RONBUNSHU 199515299-300
126. 333346 Effects of TRH analog, taltirelin hydrate (TA-0910), on the circulatory and respiratory failures and viable time following hemorrhagic shock in rats. Asai H, Watanabe Y, Matsuoka Y, Kinoshita K JPN J PHARMACOL 1999 79 Suppl 1 84P